The Spanish firm Sylentis has developed a compound to treat diseases of the retina, such as age-related macular degeneration and diabetic retinopathy, which will be administered by ophthalmic drops instead of intraocular injections. The drug, which has been tested in animals, is a small interfering RNA or RNAi capable of penetrating the cells of the retina and blocking the formation of new blood vessels.

See original (not translated) news ➥


See translated news ➥